|
177Lu-Dotatate Clinical Trials
3 actively recruiting trials across 2 locations
Also known as: Lu oxodotreotide, Lutathera®, ¹⁷⁷Lu-DOTA0-TATE
Pipeline
Phase 1: 2Phase 2: 1
Top Sponsors
- University of Wisconsin, Madison1
- University of Chicago1
- European Organisation for Research and Treatment of Cancer - EORTC1
Indications
- Cancer3
- Somatostatin Receptor-positive Neuroendocrine Tumor1
- Recurrent Meningioma1
- Metastatic Pancreatic Neuroendocrine Tumor1
- Neuroendocrine Tumors1
Other1 trial
Chicago, Illinois1 trial
Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors
University of Chicago Medicine Comprehensive Cancer Center
Phase 1
Madison, Wisconsin1 trial
Using Novel Imaging to More Safely Treat Neuroendocrine Tumors
University of Wisconsin - Madison
Phase 1
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.